Amazing Results For Immune Based Treatment of Pancreatic Cancer.

Pancreatic cancer is hard to treat, with survival figures as low as 0.4% at 5 years and survival for metastatic pancreatic cancer remains less than 20% at the end of 1 year.

However, a new immune based approach is radically changing the dismal outlook for people with pancreatic cancer. Algenpantucel-L is an irradiated, live combination of two human allogeneic pancreatic cancer cell lines that express the murine enzyme α-1, 3-galactosyl transferase (αGT). Immune based reactivity against αGal epitopes in humans can trigger immune response against cancer cells. In a recent phase II clinical trial, combing Algenpantucel-L with standard chemotherapy resulted in very significant improvements in disease free and overall survival (OS) rates.

After a 33-month follow up, the 1yr OS rate was 86% compared to less than 20% for standard treatments. Amazingly, over 51% of the patients are still alive at 2 yrs and the predicted 3yr survival rate is 42%!

I like this approach because it greatly improves the survival rates for this hard to treat cancer without increasing the toxicity of the treatment.

The following is a link to a phase III clinical trial using Algenpantucel-L and that is currently recruiting patients.

Immunotherapy Study for Surgically Resected Pancreatic Cancer.

Speak Your Mind